全文获取类型
收费全文 | 32435篇 |
免费 | 1853篇 |
国内免费 | 78篇 |
学科分类
医药卫生 | 34366篇 |
出版年
2023年 | 157篇 |
2021年 | 524篇 |
2020年 | 361篇 |
2019年 | 493篇 |
2018年 | 568篇 |
2017年 | 496篇 |
2016年 | 656篇 |
2015年 | 684篇 |
2014年 | 899篇 |
2013年 | 1122篇 |
2012年 | 1665篇 |
2011年 | 1752篇 |
2010年 | 891篇 |
2009年 | 947篇 |
2008年 | 1544篇 |
2007年 | 1626篇 |
2006年 | 1516篇 |
2005年 | 1494篇 |
2004年 | 1277篇 |
2003年 | 1249篇 |
2002年 | 1130篇 |
2001年 | 1000篇 |
2000年 | 1031篇 |
1999年 | 904篇 |
1998年 | 396篇 |
1997年 | 292篇 |
1996年 | 241篇 |
1995年 | 230篇 |
1994年 | 210篇 |
1993年 | 197篇 |
1992年 | 538篇 |
1991年 | 554篇 |
1990年 | 540篇 |
1989年 | 442篇 |
1988年 | 426篇 |
1987年 | 441篇 |
1986年 | 455篇 |
1985年 | 435篇 |
1984年 | 295篇 |
1983年 | 244篇 |
1982年 | 149篇 |
1981年 | 163篇 |
1979年 | 291篇 |
1978年 | 200篇 |
1977年 | 169篇 |
1976年 | 164篇 |
1975年 | 188篇 |
1974年 | 206篇 |
1973年 | 177篇 |
1972年 | 175篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
2.
Hommes Franziska Mohsenpour Amir Kropff Dana Pilgram Lisa Matusall Svenja von Philipsborn Peter Sell Kerstin 《Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz》2022,65(1):96-106
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - Akteure der öffentlichen Gesundheit (Public Health) tragen wesentlich zu Gesundheitsschutz, -förderung und... 相似文献
3.
Katja T. Turunen Vasiliki Pletsa Panagiotis Georgiadis John K. Triantafillidis Dimitrios Karamanolis 《Nutrition and cancer》2016,68(4):560-567
The aim of the study was to determine the effect of β-glucan on the cytotoxicity and genotoxicity of polypectomized patient's fecal water (FW). Polypectomized volunteers (n = 69) were randomly assigned to consume bread with or without β-glucan, for 3 months. FW was collected at the beginning (t = 0), the 30th and 90th day and 2 wk after the intervention. Cytotoxicity and genotoxicity were estimated on Caco-2 cells, using trypan blue exclusion test and comet assay, respectively. Gastrointestinal symptoms were recorded and subjects kept a 3-day food diary at baseline and after completion. Trypan blue exclusion test revealed cell survival of approximately 87% after incubation with FW. The FW samples showed 49% genotoxicity at the baseline. Genotoxicity in the intervention group decreased during the trial reaching statistical significance on the 90th day compared to control. An increase was noticed 2 wk after the trial, but it still remained significantly lower compared to control. Group-specific analysis for β-glucan also revealed significant decrease in the genotoxicity on the 90th day compared to baseline. β-glucan ingestion in polypectomized patients significantly decreased the genotoxicity of their FW. Our findings suggest that β-glucan consumption could possibly provide protection against colon cancer development. 相似文献
4.
Wenjing Tao Miia Artama My von Euler-Chelpin Mark Hull Rickard Ljung Elsebeth Lynge Guðríður H. Ólafsdóttir Eero Pukkala Pål Romundstad Mats Talbäck Laufey Tryggvadottir Jesper Lagergren 《International journal of cancer. Journal international du cancer》2020,147(3):728-735
Obesity is a risk factor for colorectal cancer. Yet, some research indicates that weight-reducing bariatric surgery also increases colorectal cancer risk. Our study was undertaken because current evidence examining bariatric surgery and risk of colorectal cancer is limited and inconsistent. This population-based cohort study included adults with a documented obesity diagnosis in Denmark, Finland, Iceland, Norway or Sweden in 1980–2015. The incidence of colorectal cancer in participants with obesity who had and had not undergone bariatric surgery was compared to the incidence in the corresponding background population by calculating standardized incidence ratios (SIR) with 95% confidence intervals (CI). Additionally, operated and nonoperated participants with obesity were compared using multivariable Cox regression, providing hazard ratios (HR) with 95% CIs adjusted for confounders. Among 502,772 cohort participants with an obesity diagnosis, 49,931(9.9%) underwent bariatric surgery. The overall SIR of colon cancer was increased after bariatric surgery (SIR 1.56; 95% CI 1.28–1.88), with higher SIRs ≥10 years postsurgery. The overall HR of colon cancer in operated compared to nonoperated participants was 1.13 (95% CI 0.92–1.39) and 1.55 (95% CI 1.04–2.31) 10–14 years after bariatric surgery. Bariatric surgery did not significantly increase the risk of rectal cancer (SIR 1.14, 95% CI 0.83–1.52; HR 1.08, 95% CI 0.79–1.49), but the risk estimates increased with longer follow-up periods. Our study suggests that bariatric surgery is associated with an increased risk of colon cancer, while the support for an increased risk of rectal cancer was weaker. 相似文献
5.
Monika Scheer Christian Vokuhl Iris Veit‐Friedrich Marc Münter Thekla von Kalle Michael Greulich Steffan Loff Sabine Stegmaier Monika Sparber‐Sauer Felix Niggli Ruth Ladenstein Bernarda Kazanowska Gustaf Ljungman Kirsi Jahnukainen Jrg Fuchs Stefan S. Bielack Ewa Koscielniak Thomas Klingebiel 《Pediatric blood & cancer》2020,67(2)
6.
7.
Katja Kobow Christopher A. Reid Erwin A. van Vliet Albert J. Becker Gemma L. Carvill Alica M. Goldman Shinichi Hirose Iscia Lopes-Cendes Hela Mrabet Khiari Annapurna Poduri Michael R. Johnson David C. Henshall 《Epileptic Disord》2020,22(2):127-141
Epigenetics refers broadly to processes that influence medium to long‐term gene expression by changing the readability and accessibility of the genetic code. The Neurobiology Commission of the International League Against Epilepsy (ILAE) recently convened a Task Force to explore and disseminate advances in epigenetics to better understand their role and intersection with genetics and the neurobiology of epilepsies and their co‐morbidities, and to accelerate translation of these findings into the development of better therapies. Here, we provide a topic primer on epigenetics, explaining the key processes and findings to date in experimental and human epilepsy. We review the growing list of genes with epigenetic functions that have been linked with epilepsy in humans. We consider potential practical applications, including using epigenetic signals as biomarkers for tissue‐ and biofluid‐based diagnostics and the prospects for developing epigenetic‐based treatments for epilepsy. We include a glossary of terms, FAQs and other supports to facilitate a broad understanding of the topic for the non‐expert. Last, we review the limitations, research gaps and the next challenges. In summary, epigenetic processes represent important mechanisms controlling the activity of genes, providing opportunities for insight into disease mechanisms, biomarkers and novel therapies for epilepsy. 相似文献
8.
9.
Die Unfallchirurgie - Zur Diagnostik von Schultergelenkerkrankungen wird routinemäßig die Magnetresonanztomographie (MRT) durchgeführt. Diese kann entsprechend der klinischen... 相似文献